AbbVie said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 ...

San Diego-based Capstan is developing a potential first-in-class therapy to treat certain autoimmune disease by changing ...

AbbVie (ABBV) on Monday announced that it has entered into a definitive agreement to acquire privately held clinical-stage biotechnology company Capstan Therapeutics, Inc., in a bid to boost its ...

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...

Under terms of the deal, AbbVie will acquire Capstan’s lead asset, CPTX2309—an in vivo anti-CD19 CAR T-cell therapy in Phase ...

Results of two phase 2 studies suggest efgartigimod could be a potential treatment for myositis and Sjögren disease in ...

A new COVID-19 variant is spreading rapidly through the U.S. What to know about NB.1.8.1 and its symptoms in Tennessee.

NB.1.8.1 is one of the latest variants of COVID-19, a "slightly upgraded version" of the LP.8.1 variant that is prominent ...

In the fight against cancer, immunotherapy—which aims to boost the body's natural defenses against cancer—is experiencing ...

Phase 1b study supports proof-of-concept in DOK7 congenital myasthenic syndromes Advancing ARGX-119 further validates strong track record of Immunology Innovation Program (IIP), argenx's collaborative ...

Scientists at the National Institute of Environmental Health Sciences have found that dog and cat allergens are present in ...

LJI scientists have discovered that T cells may help detect Parkinson's disease years before motor symptoms appear. Your T ...